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Abstract
The  mortality  for  acute  respiratory  distress  syndrome  (ARDS)  remains  unacceptably 
high. Success in clinical trials has been limited, resulting in a lack of effective therapies to treat 
the syndrome. The projected increase in mechanically ventilated patients and global need for 
critical care services suggests that the clinical and research landscape in ARDS can no longer be 
confined to the intensive care unit (ICU). A demonstrable minority of patients present to the 
emergency department (ED) with ARDS, and ARDS onset typically occurs shortly after ICU 
admission. Furthermore, the ED is an entry point for many of the highest risk patients for ARDS 
development and progression. These facts, combined with prolonged lengths of stay in the ED, 
suggest  that  the  ED could  represent  a  window of  opportunity  for  treatment  and  preventive 
strategies, as well as clinical trial enrollment. This review aims to discuss some of the potential  
strategies which may prevent or alter the trajectory of ARDS, with a focus on the potential role  
the ED could play in reducing the burden of this syndrome. 
Keywords
acute respiratory distress syndrome, emergency department, prevention
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Introduction
The landscape of critical care provided in the emergency department
Decades  ago,  delivery  of  critical  care was envisioned to  extend from the  prehospital 
environment  and  into  the  intensive  care  unit  (ICU).  The  emergency  department  (ED)  was 
recognized as an important link in the care of the critically ill (1). Today, with over 100 million 
visits annually and increasing lengths of stay before inpatient admission, critical care is being 
provided in the ED more than ever (2, 3). With higher acuity in patient presentation, scarcity of 
available critical care beds, and impact of ED lengths of stay on critical care outcomes, the ED 
has become an increasingly important treatment location for the critically ill (3-9). Overcrowding 
is a recognized threat to patient safety, and delays in admission of critically ill patients to the 
ICU suggest that targeted interventions should be provided as soon as possible, regardless of 
patient location (4). Although time spent in the ED is a small fraction of the total inpatient stay, 
several  series  have  demonstrated  the  early  period  of  critical  illness  as  being  a  particularly 
vulnerable  time,  where  appropriate  interventions  have  potential  to  change  morbidity  and 
mortality  (10-12). Given these realities,  the ED has proven to be an ideal setting to conduct 
research of early critical illness (11, 13).
This research agenda has yet to extend to mechanical ventilation and acute respiratory 
distress syndrome (ARDS) to any great degree however (14). Observational data suggest that the 
onset of ARDS is within hours to days after ICU admission (15-19). Endotracheal intubation and 
initiation of mechanical ventilation is common in the ED  (20). Despite this, there is a lack of 
evidence  regarding mechanical  ventilation  practices  in  the  ED or  the effect  of  ED care  and 
mechanical  ventilation  on ARDS progression and outcome  (12,  21).  Therapeutic  momentum 
initiated in the ED is often continued after admission (11, 12, 22). Given the influence of early 
interventions on outcome with other time-sensitive emergencies (e.g. sepsis and trauma), there is 
potential that this paradigm can be extended to ARDS prevention and treatment as well. The aim 
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of this review is to discuss some of the early interventions that can potentially prevent or alter the 
trajectory of  ARDS, with some focus on the potential  role  the ED may play in  the care of 
patients with or at risk for ARDS.
The current landscape of ARDS
ED prevalence and rate of progression after admission 
ARDS affects  close to 200,000 patients  annually in the United States,  and despite an 
overall improvement in mortality, remains a highly lethal condition (23, 24). Survivors of ARDS 
exhibit  long-term morbidity across a wide range of important clinical outcomes, therefore its 
impact on public health is significant (23, 24). Despite extensive research, only low tidal volume 
ventilation  has  shown  consistent  survival  benefit  across  syndrome  severity,  with  prone 
positioning  beneficial  in  the  sickest  ARDS  cohort  when  instituted  early  and  for  prolonged 
periods (25-27). Prior clinical trials have focused extensively on patients in the ICU, less so in 
the operating room (OR), and little to none in the ED (14). Limited observational data focusing 
exclusively on ED patients suggests that a significant minority of patients have ARDS while in 
the ED, with a prevalence rate of 8.8% in mechanically ventilated patients with severe sepsis and 
septic shock (a high-risk cohort for the syndrome)  (12). Larger observational studies of early 
ARDS have estimated an ED ARDS prevalence between 7 and 8.7% (21, 28).
Progression to ARDS represents a seminal event for the critically ill patient, that not only 
worsens pulmonary function (Figure 1), but also increases morbidity and mortality (14). At the 
intersection between patient risk and treatment variables, ARDS can be insidious and cryptic in 
onset, and often goes unrecognized by treating clinicians; this under-recognition of ARDS may 
contribute to the suboptimal translation of outcome-improving evidence to the bedside  (Figure 
2) (29-32). Risk factors for progression to ARDS have been described for decades, yet predicting 
ARDS at an individual patient level can be difficult. ARDS, despite a consensus definition of the 
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syndrome, is likely not a “yes/no” diagnosis, but rather a spectrum of inflammatory pulmonary 
failure.  Patients  progressing  to  ARDS have  higher  levels  of  inflammatory  markers,  both  in 
bronchoalveolar lavage and serum (33). Imaging studies have shown high levels of neutrophilic 
inflammation in patients at risk for ARDS, but in whom the definitional criteria have not been 
met (NCT01486342). These data suggest that patients at high risk for ARDS have “pre-injured” 
lungs,  and  the  progression  to  ARDS  is  a  potentially  modifiable  continuum  (Figure  3).  A 
prospective,  multicenter  observational  cohort  study  assessing  patient  conditions  and  risk 
modifiers, created a lung injury prediction score (LIPS), identifying patients at high risk  (34). 
ED-based studies suggest an ARDS progression rate after admission of 27.5% in patients with 
severe sepsis and septic shock (12). Cohort studies from the ICU and one randomized controlled 
trial have cited an ARDS progression rate of 6.2% to 44% with a median onset of approximately 
2 days  (14, 33, 35). The prevalence of ARDS after ED admission, as well as the early onset, 
further suggests that therapeutic interventions in critically ill patients should not be constrained 
by the geographic location of the patient in a hospital. The time spent and treatment provided in 
the ED, and early ICU, could potentially alter the course of ARDS.
Therapy to alter the trajectory of ARDS
Mechanical ventilation strategies 
Tidal volume
Normal mammalian tidal volume, indexed to size, is less than 7mL/kg, and was the tidal 
volume  target  used  in  a  landmark  ARDS  clinical  trial  (25,  36).  The  success  of  that  trial 
comparing  relatively  normal  tidal  volume  to  a  “conventional”  tidal  volume  showed  that 
essentially normal tidal volume improved outcome. Despite the short- and long-term outcome 
benefit  of low tidal  volume ventilation in  ARDS, adherence to this  strategy in  ICU patients 
remains poor (32). In patients without ARDS, there is no consensus on the most appropriate tidal 
6
AC
CE
PT
ED
volume to use, and this represents an area of debate  (37-40). In patients at very low risk for 
ARDS, especially with an exposure time to mechanical ventilation that is limited (e.g. healthy 
elective surgical patients), the chosen tidal volume strategy may not be clinically important (41). 
However, an increase in serum and bronchoalveolar lavage biomarkers suggests that deleterious 
mechanical ventilation can induce lung damage even with very time-limited ventilation (42-46). 
Recent  data  also  showed  that  lung-protective  ventilation  in  the  OR  was  associated  with  a 
decrease in the composite outcome of major pulmonary complications and a trend in reduction of 
ARDS in elective abdominal surgical patients (47). 
In contrast to most OR patients, mechanically ventilated ED patients will be admitted to 
the ICU and have a much longer exposure to mechanical ventilation  (12). In these pre-injured 
lungs,  conventional  tidal  volume may serve as  another  “hit”,  promoting  the  development  of 
ARDS after ICU admission (33). Many mechanically ventilated ED patients are exposed to high 
tidal volume and lung-protective ventilation is uncommon in these patients (12, 21).             
Clinical data suggests a causal link to tidal volume and ARDS progression in critically ill 
patients (15, 16, 18, 33, 48-50). In the only randomized ICU trial on this topic to date, ventilation 
with 6mL/kg predicted body weight (PBW) vs. 10mL/kg PBW showed a 10.9% absolute risk 
reduction for ARDS progression,  although the trial  was stopped early for safety  (33, 51).  A 
recent systematic review and meta-analysis showed a decrease in ARDS development with the 
use  of  lower  tidal  volume  (52).  Another  systematic  review  which  included  only  studies 
examining tidal volume in isolation, also showed that the majority of data suggests that higher 
tidal  volume  is  associated  with  ARDS progression  (14).  These  findings  are  physiologically 
consistent with randomized controlled trials  (RCT) demonstrating that  ventilation with lower 
tidal volume reduces mortality in existing ARDS (25, 53, 54). These reviews also showed that 
the use of low tidal volume in the OR and ICU is not harmful in patients without ARDS (14, 52). 
A similar safety profile should be seen in the ED, given that respiratory rate is adjusted to meet 
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metabolic  and  ventilatory  demands,  and  positive  end-expiratory  pressure  is  used  to  prevent 
atelectasis (55).
Given the risk of progression to ARDS after emergency admission, the early progression 
to ARDS after admission from the ED, and a lack of ED mechanical ventilation trials, low tidal  
volume ventilation initiated in the ED should be studied further. 
Positive end-expiratory pressure (PEEP)
Repetitive opening and closing of alveolar units at low lung volumes can contribute to 
injury (i.e.  atelectrauma).  In  patients  with hypoxia  due  to  atelectasis,  alveolar  edema and/or 
volume  loss,  PEEP  serves  to  restore  functional  residual  capacity  (FRC)  and  prevent  end-
expiratory volume loss (derecruitment) (56). Animal and ex-vivo lung model data has shown that 
PEEP can protect the lung when compared to no, or very little, PEEP (57, 58). Beyond that, the 
optimal level to set PEEP is less clear. In patients with established ARDS already receiving low 
tidal  volume  ventilation,  higher  PEEP  levels  were  not  associated  with  improved  clinical 
outcomes,  though  a  systematic  review  and  meta-analysis  suggested  that  patients  with  more 
severe ARDS may benefit from higher PEEP(59-62). 
The majority of patients in the ED in our center are treated with a PEEP of 5 cm H 2O 
(12).  In  OR  patients,  higher  PEEP  levels  are  associated  with  a  decrease  in  inflammatory 
mediators,  suggesting that  a potential  biological  signal  for protection exists  (44,  63).  Higher 
levels of PEEP will improve oxygenation and lung compliance, but the use of higher PEEP in all  
patients to prevent lung injury cannot be recommended at this time, as it is possible that higher 
PEEP may overdistend ventral lung units and promote lung injury (60-62, 64). However, obesity 
is a known risk factor for ARDS development, as these patients have elevated pleural pressure 
and are therefore prone to end-expiratory alveolar collapse (12, 65). These patients may be better 
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suited to higher PEEP levels for ARDS prevention, as well as frequent re-positioning, and the 
use of prophylactic prone or semi-prone position (55, 66).
Airway pressure release ventilation (APRV)
The manner  in  which the lung is  strained influences  the development  of lung injury. 
Repetitive, breath-by-breath tidal ventilation appears to be more damaging than static strain and 
deformation  (67-69).  Whereas  conventional  modes  of  mechanical  ventilation  elevate  airway 
pressure  up  from  a  set  baseline  to  accomplish  tidal  ventilation,  APRV  employs  sustained 
pressure over time to maintain recruitment and mean airway pressure. In an animal model, the 
early application of APRV before clinical lung injury, resulted in less pulmonary inflammation 
and  edema,  with  preserved  gross  and  histological  lung  architecture  (70,  71).  The  clinical 
application of this mode of ventilation in a single center has been associated with low incidence 
of  ARDS  in  a  trauma  population  as  well  but  no  controlled  human  studies  have  uniformly 
supported this practice (72). There is a theoretical concern for uncontrolled, large tidal volumes 
with APRV, as manifested by large volumes during the release phase. How these large volumes 
potentially contribute to lung injury, given the more static nature of APRV, is not fully known. 
Non-invasive ventilation 
The use of non-invasive ventilation is common in ED patients with dyspnea,  and has 
been shown to reduce mortality in patients with reversible causes of respiratory failure, such as 
cardiogenic  pulmonary  edema  and  chronic  obstructive  pulmonary  disease  (73,  74).  Data 
supporting its use in prevention of ARDS is less robust. Several small studies have shown a 
decrease  in  intubation  rates  with  early  application  of  non-invasive  ventilation  in 
immunocompromised patients (75, 76). However, given the limited data, and with a failure rate 
of close to 50% in lung injury patients, the use of non-invasive ventilation should be assessed on 
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an individual patient-level basis, with frequent reassessment of pulmonary mechanics in effort to 
avoid delay of appropriate and timely endotracheal intubation (77). Delayed intubation, in favor 
of a trial of non-invasive ventilation, has been associated with an increase incidence in adverse 
events, such as cardiac arrest, nosocomial pneumonia, and stress ulcers (78).
Non-ventilatory strategies 
Fluid management
The  Berlin  definition  of  ARDS  removed  the  requirement  for  a  pulmonary  artery 
occlusion pressure ≤18mmHg to distinguish between ARDS and volume overload  (79).  This 
change was  more  of  a  reflection  of  the  limitations  of  that  hemodynamic  parameter  and the 
declining use of pulmonary artery catheters,  rather  than demoting the importance of fluid in 
ARDS pathophysiology. Elevated left atrial pressure and ARDS frequently coexist, suggesting 
that any increase in edema-promoting forces can increase edema and worsen pulmonary function 
(80). Edema in injured lungs is both oncotic (e.g. capillary leak) and hydrostatic in nature. This  
suggests (based on Starling forces) that actively lowering hydrostatic pressures (or at minimum 
preventing unnecessary volume administration) should be beneficial.  The association between 
volume excess and clinical outcomes across multiple patients cohorts (e.g. sepsis, mechanical 
ventilation, elective surgery, and acute kidney injury) is being increasingly recognized (81-88).
With respect to ARDS, many clinical scenarios that predispose to the syndrome can be 
associated with extensive fluid requirements during resuscitation (e.g. septic shock and trauma). 
While  it  seems  paradoxical  that  aggressive  fluid  resuscitation  could  decrease  ARDS,  this 
highlights the importance of  timing in fluid administration. In patients with severe sepsis and 
septic shock, early “aggressive” fluid administration was associated with a decrease in the need 
for mechanical ventilation, as well as decreased inflammatory biomarkers, suggesting that early 
reversal of global tissue hypoxia promotes pulmonary integrity at an endothelial and epithelial  
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level  (11, 89). In a cohort study of patients with lung injury and sepsis, achievement of early 
adequate  fluid resuscitation  and late  conservative  fluid management  was associated  with the 
greatest survival benefit (90).  In a randomized trial of patients with pulmonary edema, a lower 
fluid  balance  was  associated  with  fewer  ventilator  and  ICU  days  (91).  With  the  use  of  a 
conservative  fluid  strategy  and  diuresis,  the  Fluids  and  Catheter  Treatment  Trial  (FACTT) 
increased ventilator-free days with no deleterious effect on organ perfusion in hemodynamically 
stable ARDS patients (92).
Observational  data  from  both  the  ICU  and  OR  suggest  that  fluid  management  is 
associated  with  progression  to  ARDS  as  well  (18,  93-96).  Fluid  administration  improves 
perfusion only if it increases stroke volume, and only about 50% of ICU patients are preload-
responsive (97). Once early tissue hypoperfusion is corrected, a conservative fluid strategy and 
diuresis should be favored. At a minimum, further fluid administration should be discouraged. 
The general consensus for most critically ill ED patients at risk for ARDS, is that early liberal 
fluid  administration  to  reverse  tissue  hypoperfusion  should  be  employed  when  preload-
responsiveness  has been established.  An unanswered question includes  the true incidence  of 
preload-responsiveness in critically ill ED patients at risk for ARDS. 
Blood product transfusion
The use of blood products is associated with progression to ARDS in at-risk patients. As 
an inflammatory syndrome characterized by alveolar epithelial and vascular endothelial injury, 
ARDS is notable for early neutrophil sequestration in the lung (98). Transfusion of blood product 
is associated with transmission of leukocyte antibodies and biologically active mediators (e.g. 
lipids  and cytokines),  thought  to  play  a  role  in  the  pathogenesis  of  transfusion  transfusion-
associated acute lung injury (TRALI). The diagnosis of classic TRALI requires a clear temporal 
relationship to transfusion, with signs and symptoms occurring within 6 hours. Observational 
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data suggests  a  classic  TRALI incidence  of  close to  10% in critically  ill  patients  (99,  100). 
However, in critically ill patients, multiple studies have shown the transfusion of any amount of 
blood product to be associated with the progression to ARDS in at risk patients (15, 17-19, 49, 
101-105). Expanding the definition of TRALI beyond six hours (i.e. delayed TRALI syndrome), 
shows that  lung injury may occur  in  up to  25% of  critically  ill  patients  within 72 hours  of  
receiving  a  blood  transfusion  (106).  Recipient  and  transfusion  risk  factors,  such  as  female 
donors, suggest that this incidence is modifiable, and potential targets exist for reducing TRALI 
(107).
There has been a general decrease in transfusion in the ICU, but transfusion patterns and 
influence of ED transfusion on ARDS has remained largely unexplored. Extrapolation of data 
from ICU patients without ARDS at the time of admission, suggests early transfusion plays a 
role in ARDS development  (15, 17-19, 49). However, in many of these observational studies, 
ARDS  progression  was  also  associated  with  other  factors  (e.g.  higher  tidal  volumes,  fluid 
balance,  etc.),  highlighting  the complex pathophysiologic  interactions  in ARDS development 
(14). Similar to fluid administration, transfusion may also depend on timing of administration. 
Early administration of PRBCs as part of a quantitative resuscitation strategy for severe sepsis 
was associated with a decrease in mechanical  ventilation,  or a trend in that direction,  in the 
majority of published data (11, 108). However, these trials were not designed to isolate the effect 
of transfusion. PRBC administration in this clinical scenario is aimed at improving low central 
venous oxygen saturation (ScvO2). Observational data suggests that transfusion does not improve 
ScvO2 or organ function (109). In our opinion, given the fact that the weight of evidence does not 
show a benefit with PRBC transfusion, the decision to transfuse should be individualized at the 
patient level, as opposed to a priori hematocrit triggers. Transfusion should be reserved only for 
anemic patients with persistent evidence of tissue hypoperfusion, after a careful assessment of 
risk:benefit.  Ongoing  multicenter  trials  [e.g.  Protocolized  Care  for  Early  Septic  Shock 
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(ProCESS)  NCT00510835]  will  hopefully  better  define  the  risk:benefit  of  potential  harm 
associated with early transfusion versus persistent global tissue hypoxia (which transfusion may 
improve). 
Pharmacotherapy
No pharmacological agent designed to alter the primary pathophysiology of ARDS (i.e. 
beyond supportive care) has improved clinical  outcome.  Several  agents  have been tested for 
prevention  of  ARDS  progression.  In  a  propensity-matched  observational  study,  systemic 
corticosteroids did not reduce the incidence of ARDS (110). A single center study showed that 
prehospital antiplatelet therapy was associated with a reduced incidence of ARDS (111). Using 
propensity  score  matching,  a  multi-center  study  failed  to  show  statistical  significance  with 
prehospital aspirin therapy, however the multivariable effect size remained fairly consistent and 
statistical  significance  was  almost  achieved  (p  =  0.07)  (112).  Similarly,  propensity  score 
matching analysis failed to show a decrease in ARDS with statin therapy, in contrast to prior 
published data  (113, 114). Therapy with azithromycin was shown to decrease mortality and a 
13.1% absolute risk reduction in incidence of ARDS (p = 0.064) in patients with Pneumococcal 
pneumonia  (115). In patients with lung injury,  the receipt of a macrolide has been shown to 
decrease  mortality  and  mechanical  ventilation  days,  in  contrast  to  patients  receiving  a 
fluoroquinolone or cephalosporin (116). Given the pleiotropic effects of macrolides, prospective 
trials addressing the impact of these agents on ARDS prevention and treatment are warranted 
(117).  Multiple  clinical  trials  targeting  various  pathways,  such  as  alveolar  coagulation, 
inflammation,  and  alveolar  fluid  balance  are  currently  in  progress 
(http://clinicaltrials.gov/ct2/results?term=ARDS+and+prevention&pg=1).
High minute ventilation and respiratory drive is common in early lung injury, as alveolar 
edema and respiratory system compliance worsen. With the induction of paralysis and control of 
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the respiratory pattern, neuromuscular blockers (NMB) can mitigate lung injury (theoretically) 
by  removing  dysynchrony  and  the  associated  over-distention  and  end-expiratory  collapse 
associated with vigorous spontaneous respirations. Furthermore, a decrease in oxygen demand 
and subsequent  cardiac output through an injured lung, should reduce venous admixture and 
pulmonary  edema  (118).  A small  RCT also  showed that  a  short  duration  of  NMB reduced 
pulmonary  and  systemic  inflammation  (119).  A multicenter  database  study of  mechanically 
ventilated severe sepsis patients found that the receipt of neuromuscular blockers was associated 
with a  reduction  in  in-hospital  mortality  (120).  In  a  multicenter  RCT of  patients  with  early 
(within  48  hours),  severe  (PaO2:FiO2  <150)  ARDS,  a  48  hour  infusion  of  cisatricurium was 
associated  with decreased hospital mortality censored at 90 days  (121). However, this benefit 
was  restricted  to  the  subgroup  of  patients  with  a  PaO2:FiO2  <120.  These  findings  make 
recommending early NMB for patients at risk for ARDS difficult, and perhaps restricted only to 
a very small cohort, such as LIPS ≥ 8 (≈35% chance of developing ARDS) with high ventilatory 
demands (34, 118).
Early treatment of infection
A delay in appropriate antimicrobial therapy increases the risk of death in patients with 
bacterial septic shock and increases progression rate to ARDS (17, 122). Globally, influenza is 
one of the most important causes of respiratory failure and ARDS, especially during seasonal 
outbreaks and pandemics  (123). The majority of hospitalized patients with seasonal influenza 
present from the ED  (124). Trials conducted primarily in healthy individuals in the outpatient 
setting have demonstrated that neuraminidase inhibitors can reduce illness duration for influenza 
patients treated within 48 hours of illness onset  (125). Data is limited with respect to patients 
with more severe influenza. In patients hospitalized with influenza, oseltamivir has been shown 
to reduce mortality and decrease lengths of stay (126-130). A minority of patients receive this 
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therapy however (124). In patients with pandemic influenza A (H1N1), the most common cause 
of  death  is  pneumonia  and  ARDS  (131).  Observational  data  suggest  that  treatment  with 
neuraminidase inhibitors reduces pneumonia,  illness severity,  and mortality  (132-134). While 
antiviral therapy for prevention of ARDS has not been specifically studied, early treatment with 
antivirals has also been associated with a decrease in mechanical ventilation days in critically ill  
patients  (135).  It  is  recommended  that  early  neuraminidase  therapy  be  initiated  as  early  as 
possible to reduce complications from influenza for any patient  with confirmed or suspected 
influenza who is hospitalized, is critically ill, or is at higher risk for complications (125). 
Extracorporeal support
The use of extracorporeal membrane oxygenation (ECMO) and pumpless extracorporeal 
lung  assist  (pECLA)  in  respiratory  failure  is  increasing  in  frequency.  By  allowing  further 
limitation of tidal volume, end-inspiratory stretch, and regional overdistention, these strategies 
provide significant lung rest, potential for total strain prevention, and limitation of lung injury 
propagation. The current evidence to support ECMO in ARDS can be summarized as follows: 
Registry data points to a greater ECMO benefit when instituted early; prospective observational 
trials  during the H1N1 influenza outbreak suggest that early ECMO referral  to high volume 
centers  is  feasible  and  associated  with  high  survival  rates;  a  multicenter  RCT showed  that 
referral to an ECMO-capable center was associated with a 16% absolute risk reduction for death 
or severe disability at six months (136-141). Whether the benefit lies in the ECMO itself or the 
referral to highly specialized centers is unclear. 
The application of extracorporeal technology to  prevent lung injury may seem unlikely 
when considering that benefit in ARDS seems to be restricted to the sickest cohort of patients. 
However, support for prevention could be extrapolated from the benefit when applied in early 
ARDS, as well as technological advances which have increased ease of use and safety profile. 
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New pumpless devices can effectively support gas exchange and facilitate very low tidal volume 
ventilation  (142-144). This has allowed full support without the aid of an endotracheal tube in 
case reports (145, 146). 
Looking forward, with evidence suggesting that normal lungs can be damaged by even 
low stretch ventilation,  the early application of pECLA,  in experienced, high-volume centers, 
could allow lung rest without the aid of a mechanical ventilator in a select cohort of patients at 
risk  for  ARDS  (147).  This  expansion  of  extracorporeal  support  beyond  life-threatening 
hypoxemia to life-threatening ventilator-associated lung injury remains to be tested (148).
Extending ICU-level supportive care to the ED and prehospital environment
Until  better  genotyping and phenotyping of the individual patients comprising critical 
care  syndromes  (e.g.  sepsis  and  ARDS)  occurs,  it  seems  unlikely  that  narrow  mechanistic 
intervention  trials  will  work  (149, 150).  Attempts  at  de-individualizing  care,  at  the clinician 
level, have improved survival in sepsis (151). Similarly, the Checklist for Lung Injury Prevention 
(CLIP) attempts to standardize care for patients at risk for ARDS by incorporating evidence-
based practices shown to benefit critically ill  patients in general  (152). While elucidating the 
contribution of individual elements (e.g. head of bed elevation and oral care with chlorhexidine) 
will likely be topics of academic debate, the efficacy to side effect profile, as well as common 
sense,  dictate  that  standard ICU-level  of care should be extended to the ED and prehospital 
environment when feasible.
Conclusion
The prevalence and clinical trajectory of ARDS is modifiable. The physiology of lung 
injury, as well as previous trial failures, dictate that research and intervention should be extended 
to earlier times of patient presentation. While the ED has proven to be a highly relevant location 
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for the treatment of time-sensitive emergencies (e.g. stroke, sepsis), this has yet  to extend to 
mechanical ventilation and ARDS. Several knowledge gaps exist with respect to the long term 
effects  of  ED  interventions  on  ARDS  progression  and  should  be  investigated  further.  The 
optimal intervention for ARDS prevention while likely be some combination of ventilatory and 
non-ventilatory  strategies,  along  with  a  multidisciplinary  collaboration  between  emergency 
physicians, intensivists, nurses, and respiratory therapists. 
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Figure Legends
Figure 1. Observational data suggests that acute respiratory distress syndrome (ARDS) onset 
ranges from 5 hours to 3.7 days, with a median onset of 2 days. Increasing acuity and prolonged 
emergency department (ED) lengths of stay (LOS) for the critically ill  suggests that the time 
spent  in the ED may represent  a  window of  opportunity (“golden hours”)  to  initiate  ARDS 
prevention strategies.
Solid  circles  indicate  patients  not  progressing  to  ARDS  and  dashed  circles  indicate  the 
development of ARDS.
PaO2:FiO2- partial pressure of arterial oxygen:fraction of inspired oxygen; CRS- respiratory system 
compliance; ED- emergency department; LOS- length of stay
Figure 2. Observational data, including patients dying with acute respiratory distress syndrome 
(ARDS) and receiving post-mortem examinations, reveal that clinical recognition and diagnosis 
of ARDS is missed in a significant percentage of patients. [30-32]
Figure  3. Simplified  schematic  of  the  pathogenesis  of  acute  respiratory  distress  syndrome 
(ARDS) with respect to time. After an inciting event, capillary endothelial and alveolar epithelial 
injury can occurs in minutes to hours. Activated immune cells (e.g. monocytes and macrophages) 
contribute  to  a  cytokine-mediated  inflammatory  response.  This  serves  to  recruit  neutrophils, 
which play a critical role in ARDS initiation and propagation, through the injured endothelium. 
Protein-rich pulmonary edema and subsequent surfactant loss lead to alveolar collapse, hypoxia, 
and reduced lung compliance [133,134]. If the primary injury is robust enough, or if modifiable 
secondary injuries occur (e.g. high tidal volume, transfusion, delayed sepsis treatment), ARDS 
develops, with a typical median onset of two days. Many of these pathogenic mechanisms for 
ARDS initiation occur prior to clinical evidence of the syndrome, and this window of pre-clinical 
injury forms the basis for ARDS preventive measures. 
TNF: tumor necrosis factor; IL: interleukin; ARDS: acute respiratory distress syndrome
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